Lifestyle · World

FDA Panel Reviews Innovative mRNA Flu Vaccine from Moderna

1 sourceFirst reported 1 month agoUpdated 1 month ago

AI summary: catch up in 20 seconds

The FDA panel is discussing a new flu vaccine using mRNA technology.
Moderna's vaccine, named mFlusvia, targets individuals aged 50 and older.
The meeting is part of the process towards potential approval ahead of flu season.
This vaccine technology previously played a crucial role in combating Covid-19.

Generated by AI from the 1 sources below · always verify with the originals

AI summary: catch up in 20 seconds

Summarising the coverage…

Generated by AI from the 1 sources below · always verify with the originals

All coverage (1)

Sign in to join the discussion.

No comments yet. Be the first to join the discussion.

AI summary: catch up in 20 seconds

The FDA panel is discussing a new flu vaccine using mRNA technology.
Moderna's vaccine, named mFlusvia, targets individuals aged 50 and older.
The meeting is part of the process towards potential approval ahead of flu season.
This vaccine technology previously played a crucial role in combating Covid-19.

Generated by AI from the 1 sources below · always verify with the originals